CONGRESS PRESENTATIONS

CONGRESS PRESENTATIONS

HIV Glasgow 2020

HIV Drug Therapy Glasgow 2020

October 5-8, 2020
Virtual

Posters

Posters

Dolutegravir

Cahn P, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naïve adults with HIV-1 infection: 3-year results from the GEMINI studies. Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Poster P018.

Noe S, et al. 12-months outcomes of dolutegravir/rilpivirine in virologically suppressed HIV-infected patients: real-world data from the German JUNGLE cohort. Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Poster P039.

Postel N, et al. Real-world data from the prospective URBAN cohort study on the use of dolutegravir (DTG) + lamivudine (3TC) in ART-naïve and pre-treated people living with HIV in Germany. Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Poster P044.

Rolle CP, et al. Feasibility, efficacy, and safety of using dolutegravir/lamivudine (DTG/3TC) as a first-line regimen in a test-and-treat setting for newly diagnosed PLWH: the STAT study. Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Poster P020.

Spinelli F, et al. Efficacy and safety of dolutegravir in treatment-naive people living with HIV-1 stratified by age: meta-analysis of 48-week results from ARIA, FLAMINGO, SINGLE, and SPRING-2. Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Poster P010.

Cabotegravir

Akinwunmi B, et al. Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and physicians in western Europe. Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Poster P014.

Benn P, et al. Outcomes for women receiving long-acting cabotegravir + rilpivirine monthly and every 2 months : ATLAS-2M study Week 48 results. Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Poster P017.

Chounta V, et al. Comparability of 48-week efficacy and safety of cabotegravir + rilpivirine long-acting every 8 weeks to standard of care in suppressed HIV-1-infected patients. Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Poster P011.

Chounta V, et al. Subgroup analysis of patient-reported outcomes among participants in two phase III clinical trials of long-acting cabotegravir and rilpivirine (ATLAS and FLAIR). Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Poster P012.

Parker B, et al. Cost-utility analysis of long-acting cabotegravir + rilpivirine for the treatment of HIV infection in the United Kingdom. Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Poster P030

Swindells S, et al. Cabotegravir + rilpivirine long-acting as HIV-1 maintenance therapy: ATLAS week 96 results. Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Poster P006.

Fostemsavir

Gartland M, et al. Clinical significance of gp120 polymorphisms, temsavir IC50FC, and HIV-1 subtype in BRIGHTE. Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Poster P019.

Moore K, et al. Evaluation and clinical application of fostemsavir co-administration with tuberculosis medications. Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Poster P098.

Nwokolo N, et al. Fostemsavir and ethinyl estradiol drug interaction: clinical application for coadministration. Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Poster P102.

Parasrampuria R, et al. Fostemsavir exposure-response relationships in treatment-experienced HIV patients. Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Poster P021.

Thakkar N, et al. Model-based approach of dose selection and optimal pharmacokinetics sampling of fostemsavir for pediatric patients with multidrug resistant HIV-1 infection. Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Poster P022.

Disease State

Okoli C, et al. Self-care and involvement in managed care among people living with HIV in Europe. Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Poster P033.

Okoli C, et al. What about me? The unmet needs of men who have sex with women and differences in HIV treatment experiences, perceptions, and behaviors by gender and sexual orientation in 25 countries. Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Poster P016.

Spinelli F, et al. Beyond viral load: exploring mediating factors for the gap in optimal self-rated health by adherence status among older adults living with HIV. Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Poster P031.

Spinelli F, et al. Social, psychological, and treatment-related challenges of a new HIV diagnosis in old age. Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Poster P008.

Oral Presentations

Oral Presentations

 

Dolutegravir

Van Wyk J, et al. Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 weeks (TANGO study). Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Oral presentation O441.
Thursday, October 8, 2020, 12:15 PM - 12:28 PM EST

Cabotegravir

D’Amico R, et al. Safety and efficacy of cabotegravir + rilpivirine long-acting with and without oral lead-in: FLAIR Week 124 results.
Thursday, October 8, 2020, 06:58 AM - 07:06 AM EST

Margolis D, et al. A combination of viral and participant factors influence virologic outcome to long-acting cabotegravir and rilpivirine: multivariable and baseline factor analyses across ATLAS, FLAIR, and ATLAS-2M phase III studies. Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Oral Presentation O442.
Thursday, October 8, 2020, 12:28PM - 12:41 PM EST

My MSL

Enter zip code to find your MSL contact.